FINWIRES · TerminalLIVE
FINWIRES

Update: MaxLinear Shares Jump After Q1 Financial Results

-- (Updates with the latest stock movement in the first paragraph and headline.)

MaxLinear (MXL) shares were up roughly 75% in Friday trading after the company posted a swing to Q1 adjusted earnings and higher revenue in addition to issuing higher-than-expected Q2 sales guidance on Thursday.

The company reported Q1 adjusted earnings late Thursday of $0.22 per diluted share, swinging from a loss of $0.05 a year earlier.

Analysts polled by FactSet expected EPS of $0.18.

Revenue for the three months ended March 31 was $137.2 million, up from $95.9 million a year earlier.

Analysts surveyed by FactSet expected $134.6 million.

For Q2, the company expects revenue of $160 million to $170 million. Analysts expect $137.1 million.

The company also amended its credit agreement with certain lenders to extend the maturity of the revolving credit facility to March 2028 and also increased the amount available under the facility to $130 million.

Price: $59.93, Change: $+25.68, Percent Change: +74.98%

Related Articles

Research

Research Alert: CFRA Raises Rating On West Pharmaceutical Services, Inc. To Buy From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price is $350, up from $267 and represents 41x our 2026 EPS estimate (up $0.63 to $8.53; 2027's up $0.61 to $9.42), near WST's five-year forward average of 42x. Our valuation reflects our view of the strength of the High-Value Products (HVP) business, as well as a growing market for GLP-1 elastomer sales and significant balance sheet health (negative net debt). We anticipate new drug development will support the HVP business, as biologics made up around 42% of sales during Q1 2026. Further, GLP-1 drug demand may provide a new catalyst for sales of syringes. WST secured a multiyear contract with Novo Nordisk for all its GLP-1 primary packaging elastomer needs, and GLP-1 elastomers comprised 10% of Q1 2026 sales. Combined with sales in the West Vantage segment, GLP-1 exposure made up 18% of total net sales during the quarter. The Annex 1 regulatory updates for medical manufacturing also provide tailwinds for HVP via quality upgrade projects for existing WST components, in our view.

$WST
Insider Trading

Goldman Sachs Group Insider Sold Shares Worth $1,044,782, According to a Recent SEC Filing

Alex S Golten, Chief Risk Officer, on April 23, 2026, sold 1,116 shares in Goldman Sachs Group (GS) for $1,044,782. Following the Form 4 filing with the SEC, Golten has control over a total of 2,578 common shares of the company, with 2,578 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886982/000205084926000015/xslF345X05/wk-form4_1777061036.xml

$GS
Australia

Sector Update: Energy Stocks Softer Late Afternoon

Energy stocks declined late Friday afternoon, with the NYSE Energy Sector Index shedding 0.7% and the State Street Energy Select Sector SPDR ETF (XLE) decreasing 0.2%.The Philadelphia Oil Service Sector Index rose 1.8%, and the Dow Jones US Utilities Index added 0.1%.West Texas Intermediate crude oil fell 1.2% to $94.68 a barrel, and global benchmark Brent rose 0.5% to $105.64 a barrel. Henry Hub natural gas futures shed 3.7% to $2.52 per 1 million BTU.In corporate news, TotalEnergies (TTE) secured financing for its Mirny onshore wind and battery energy storage system project in southeast Kazakhstan. The stock fell 0.7%.X-Energy (XE) shares jumped 27% following their debut on Nasdaq.SLB (SLB) reported mixed Q1 results, reflecting headwinds from the Middle East conflict. The shares rose 2.8% as revenue topped estimates, while earnings fell.BP (BP) and Repsol have been accused of anti-competitive practices in a complaint filed with the European Commission by Spanish fuel wholesaler Hatta Energy, Bloomberg reported. BP shares were down 0.4%.

$BP$SLB$TTE$XE